{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&humanIndexable=true&creator.label=Biography+information+for+Sir+Christopher+Chope", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&humanIndexable=true&creator.label=Biography+information+for+Sir+Christopher+Chope", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&humanIndexable=true&_metadata=all&creator.label=Biography+information+for+Sir+Christopher+Chope", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=0&humanIndexable=true&creator.label=Biography+information+for+Sir+Christopher+Chope", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&humanIndexable=true&creator.label=Biography+information+for+Sir+Christopher+Chope", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&humanIndexable=true&creator.label=Biography+information+for+Sir+Christopher+Chope", "items" : [{"_about" : "http://data.parliament.uk/resources/1736625", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736625/answer", "answerText" : {"_value" : "<p>Whilst there are currently no plans to meet with Professor Adam Finn, the Government continues to listen carefully to the concerns raised about the Vaccine Damages Payment Scheme. As part of this consideration, my Rt Hon. Friend, the Secretary of State for Health and Social Care met recently with Vaccine Injured and Bereaved UK, and other representatives of those who have suffered harm.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736625/answer/previousversion/13328", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
          }
          , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
          , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        }
        , "questionFirstAnswered" : [{"_value" : "2024-10-30T16:03:34.6Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Vaccine Damage Payment Scheme"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will meet with Professor Adam Finn to discuss the Vaccine Damage Payment Scheme (a) 60% threshold, (b) levels of payments in the context of levels of inflation and (c) the potential impact of those factors on levels of public confidence in vaccines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "10667"}
    , {"_about" : "http://data.parliament.uk/resources/1736626", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736626/answer", "answerText" : {"_value" : "<p>The AstraZeneca COVID-19 vaccine was first deployed in England in January 2021. Having reached the end of the supply agreement with the Government, the vaccine has not been used in the United Kingdom\u2019s COVID-19 vaccination programme since 2022. Since September 2021, in line with advice from the Joint Committee on Vaccination and Immunisation, the vaccines deployed in the national programme have primarily been mRNA vaccines that were considered to provide a strong booster response.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736626/answer/previousversion/13332", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
          }
          , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
          , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        }
        , "questionFirstAnswered" : [{"_value" : "2024-10-30T14:40:44.563Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, when the use of the AstraZeneca Covid-19 vaccine Vaxrevia ended in the UK; and for what reason that vaccine is no longer available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "10668"}
    , {"_about" : "http://data.parliament.uk/resources/1736629", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736629/answer", "answerText" : {"_value" : "<p>It would not be appropriate for the Government to comment on individual claims or cases whilst there is ongoing litigation. It is right that such matters follow the appropriate legal process, which can take time. There are, however, currently no plans to launch a consultation on increasing the limitation period for court claims relating to COVID-19 vaccines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736629/answer/previousversion/13329", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
          }
          , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
          , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        }
        , "questionFirstAnswered" : [{"_value" : "2024-10-30T15:12:47.437Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 October 2024 to Question 9409 on Vaccine Damage Payment Scheme, if he will launch a consultation with Cabinet colleagues on the potential merits of bringing forward legislative proposals to increase the limitation period for court claims relating to Covid-19 vaccines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "10669"}
    , {"_about" : "http://data.parliament.uk/resources/1736630", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736630/answer", "answerText" : {"_value" : "<p>My Rt Hon. Friend, the Secretary of State for Health and Social Care met with the families of those who have suffered serious side effects from the Astra Zeneca COVID-19 vaccine on 11 September 2024. The families raised the need for the reform of the Vaccine Damage Payment Scheme, and they requested a compensation scheme for those affected. My Rt Hon. Friend, the Secretary of State for Health and Social Care listened to their concerns and agreed that the Government will look closely at this, as it continues to learn and apply the lessons of the COVID-19 pandemic.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736630/answer/previousversion/13327", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
          }
          , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
          , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        }
        , "questionFirstAnswered" : [{"_value" : "2024-10-30T15:56:01.107Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, on what date he met representatives of those (a) injured and (b) bereaved as a result of Covid-19 vaccine damage; and what steps he has taken as a result of that meeting.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "10670"}
    , {"_about" : "http://data.parliament.uk/resources/1736632", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1736632/answer", "answerText" : {"_value" : "<p>No modifications or line extensions to the original vaccines have been introduced to reduce side effects.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736632/answer/previousversion/13331", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
          }
          , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
          , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        }
        , "questionFirstAnswered" : [{"_value" : "2024-10-30T14:44:14.317Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 October 2024 to Question 9410 on Coronavirus: Vaccination, whether any line extensions to covid-19 vaccinations have been authorised to tackle reported adverse side effects, other than for the side effects listed in that Answer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "10671"}
    , {"_about" : "http://data.parliament.uk/resources/1734694", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1734694/answer", "answerText" : {"_value" : "<p>We expect that individuals whose claims to the Vaccine Damage Payment Scheme (VDPS) have been rejected on the basis that they do not meet the 60% disability threshold would receive the same level of treatment and care from the National Health Service as those with any other long-term condition requiring support.<\/p><p>The VDPS is not a compensation scheme. It does not prejudice the right of the disabled person to pursue a claim for damages through the courts. Other Government support remains open to claimants with a disability or long-term health condition, including Statutory Sick Pay, Universal Credit, Employment and Support Allowance, Attendance Allowance, and Personal Independence Payments.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-10-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-10-21T15:23:16.717Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-10-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Vaccine Damage Payment Scheme"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will take steps to provide (a) healthcare and (b) financial support to people whose applications to the Vaccine Damage Payments Scheme were rejected on the basis that they do not have a severe disablement that exceeds the 60% threshold.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "9409"}
    , {"_about" : "http://data.parliament.uk/resources/1734841", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1734841/answer", "answerText" : {"_value" : "<p>The most common side effects observed with COVID-19 vaccines are pain and swelling at the injection site, tiredness, headaches, muscle and joint pain, chills, fever, and diarrhoea. These side effects are similar to those seen with other vaccines and are usually mild or moderate, and get better within a few days after vaccination. A full list of side effects is presented in the Patient Information Leaflet for each vaccine. Modifications or line extensions to the original vaccines, specifically to reduce these side effects, have not been introduced.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-10-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-10-21T15:09:36.953Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-10-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 14 October 2024 to Question 8098 on Coronavirus: Vaccination, whether any line extensions to Covid-19 vaccinations have been authorised to tackle reported adverse side effects.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "9410"}
    , {"_about" : "http://data.parliament.uk/resources/1732828", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1732828/answer", "answerText" : {"_value" : "<p>The Medicines and Health products Regulatory Agency may authorise a line extension, which is a new product authorisation linked to the original marketing authorisation. Various versions of the COVID-19 vaccines have been approved as line extensions to the original vaccines since the first COVID-19 vaccines were approved in December 2020. Variations may be requested to add an indication, dosage form, strength or pack size, which will make the vaccine available for a wider patient pool, whilst maintaining effectiveness and an acceptable safety level. For example, Pfizer, in late 2021, made an application to extend the indication of their vaccines to children between five and 11 years old in a smaller 10 micrograms per dose, and later, via the European Commission Decision Reliance Procedure, a new three micrograms per dose in infants and children between aged six months and four years old. New versions of the vaccine have also been introduced to adapt the vaccines to the new strains of the virus.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-10-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-10-14T15:31:33.96Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-10-09", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what modifications have been made to existing Covid-19 vaccine products; for what reasons were those modifications made; and when those modifications were approved by the Medicines and Healthcare Products Regulatory Agency.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "8098"}
    , {"_about" : "http://data.parliament.uk/resources/1732830", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1732830/answer", "answerText" : {"_value" : "<p>The Medicine and Healthcare products Regulatory Agency uses both observed and expected analysis in their assessment of safety signals for COVID-19 vaccines. Data obtained from the spontaneous Yellow Card reporting system, through which patients, public and healthcare professionals can report any incident associated with a medical product, was used to calculate \u2018Observed\u2019 figures. Estimated \u2018Expected\u2019 figures for pre-determined events were based on the total number of patients who had received the vaccine and the background rate of the event within a pre-pandemic period, using large electronic healthcare record databases. It should be recognised that the purpose of observed versus expected analyses is not to confirm the presence, absence, or magnitude of risks but to provide an alternative approach to rapid signal detection, in addition to disproportionality approaches, to maximise the value of spontaneous reports.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-10-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-10-14T15:32:45.277Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-10-09", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, for what reason the MHRA uses observed analyses instead of expected analyses in assessing the safety of Covid-19 vaccines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "8100"}
    , {"_about" : "http://data.parliament.uk/resources/1728037", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1728037/answer", "answerText" : {"_value" : "<p>The respiratory syncytial virus (RSV) vaccination programme for adults turning 75 years old began on 1 September 2024 in England, alongside a one-off catch-up programme to rapidly vaccinate all those already aged 75 to 79 years old. Older adults will remain eligible until the day before their 80th birthday, except for people who turn 80 years old in the first year, who have until 31 August 2025 to get vaccinated.<\/p><p>When a new vaccination programme is introduced, the Government must make difficult decisions on who to offer the vaccine to. These decisions are based on advice the Department receives from the Joint Committee on Vaccination and Immunisation (JCVI), which includes evidence of the impact a vaccination has in different groups, as well as the capacity of the system to deliver the programme alongside all other healthcare priorities.<\/p><p>The structure of an immunisation programme is dynamic and the JCVI will continue to review the data available on who should be offered an RSV immunisation. It was noted in the JCVI\u2019s advice from June 2023 that \u2018an extension to the initial programme would be considered when there is more certainty about protection in the very elderly and the real-world impact of the programme in the 75- to 80-year-olds\u2019. The JCVI\u2019s statement on the introduction of an RSV vaccination programme is available at the following link:<\/p><p><a href=\"https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023\" target=\"_blank\">https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023<\/a><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
        , "dateOfAnswer" : {"_value" : "2024-09-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-09-12T15:07:24.92Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-09-09", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Respiratory Syncytial Virus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, for what reason the respiratory syncytial virus vaccination programme does not include people who are 80 or older.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
      }
      , "tablingMemberConstituency" : {"_value" : "Christchurch"}
      , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
      ], "uin" : "4583"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=1&humanIndexable=true&creator.label=Biography+information+for+Sir+Christopher+Chope", "page" : 0, "startIndex" : 1, "totalResults" : 405, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}